EXHIBITING – BOOTH #802 AT MOLECULAR MED TRI-CON 2020March 1-4, 2020 Moscone Center, San Francisco, CA Visit our booth to learn about Flagship’s services that bring efficiencies and accuracy to clinical development by changing the paradigm of traditional pathology,...
Events
UPCOMING EVENTS
- Spatial Biology for Drug Development Summit 2023 | October 11-13, Boston, MA (Exhibitor)
- Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 3-5, San Diego, CA (Booth #716)
- American Society for Hematology (ASH) Annual Meeting & Exposition | December 9-12, San Diego, CA (Booth #3349)
5th Annual Life Science Industry Showcase – February 19, 2020
Recruiting/Exhibiting – 5th Annual Life Science Industry ShowcaseFebruary 19, 2020 Aurora, CO Visit Flagship at our table at this networking event, which connects Colorado biotech, pharmaceutical, medical device, and diagnostic companies with students from Colorado...
Markets and Markets Biomarker and Companion Diagnostics – Feb. 6-7, 2020
EXHIBITING – THE 5TH ANNUAL MARKETSANDMARKETS BIOMARKER AND COMPANION DIAGNOSTICS CONFERENCEFebruary 6-7, 2020 San Diego, CA Visit us at the show in San Diego to meet several of Flagship’s leaders in science and business and to discuss your biomarker and tissue data...
SITC 2019 – Nov. 6-10, 2019
FLAGSHIP IS PRESENTING A POSTER AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 34TH ANNUAL MEETINGNovember 6-10, 2019 Gaylord National Hotel and Convention Center, National Harbor, MD Flagship is presenting a scientific poster on November 8th at the meeting in...
Flagship Webinar – Oct 9, 2019
WEBINAR – IMPROVING PD-L1 SCORING WITH IMAGE ANALYSISOctober 9, 2019 1 PM EDT/10 AM PDT on “Improving PD-L1 Scoring with Image Analysis”.
CB&CDx – Sept 12, 2019
ANALYTICAL ADVANCEMENTS TO POWER BIOMARKER DEVELOPMENT TRACK PRESENTATION: ADDING VALUE TO TRADITIONAL IN VITRO DIAGNOSTICS (IVDS) AT WORLD CB&CDXSeptember 12, 2019 at 2:50pm The Renaissance Boston Waterfront, Boston, MA Speaker: Kelsey Weigel, PhD, Scientist II,...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Flagship Spotlight: Roberto Gianani, MD
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
Flagship Spotlight: Adam Beharry
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
White Paper: Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
PUBLICATIONS/POSTERS
Comprehensive Image Analysis Of Immunostained NSCLC Tissues Provides Necessary Context For Immune Oncology Biomarker Profiling
Key Takeaways Manual pathology assessment is challenging and variable, limiting the data interpretation required for meaningful spatial biology analysis Unlike manual assessment, artificial intelligence and machine learning technologies analyze the complex...
Artificial Intelligence Assisted Macrophage Identification in Tumor Biopsies
Key Takeaways Classifying macrophages is important in understanding response to immunotherapy, but it may be challenging to do by eye Using an immunofluorescence-guided machine learning algorithm provided accurate macrophage classification This algorithm is useful in...
Analysis of Companion Diagnostic Potentials For Multifaceted PD-L1 Assays
ABSTRACT In vitro diagnostic (IVD) approvals of qualitative immunohistochemical (IHC) assays offer unique patient selection strategies by equipping pathologists with new tools to assess tumor status including tumor immune landscape. PD-L1/PD-1 checkpoint therapies...